Journal updates

Canadian guidelines drive Lp(a) testing

March 19, 2024

A Canadian Cardiovascular Society recommendation for measuring Lp(a) at least once in a patient’s lifetime published in 2021 has had a considerable early impact on testing in the western province of Alberta. During two years after publication, 33,249 patients had a total of 37,456 Lp(a) tests.

Raised Lp(a) predicts failure to achieve LDL-C target

March 18, 2024

Elevated Lp(a) levels influence LDL-C levels and hinder the achievement of targets in patients at very high cardiovascular risk, conclude researchers who carried out a cross-sectional study in a cardiology department in Spain.

Lp(a) more atherogenic than LDL-C

March 17, 2024

Lp(a) may be as much as six times more atherogenic than LDL-C, according to results of genome-wide association studies (GWAS) using UK biobank data from over 500,000 people. Researchers identified two clusters of single nucleotide polymorphisms (SNPs): one comprising 107 variants linked to Lp(a) mass concentration, the other with 143 variants linked to LDL concentration.

EAS answers questions on Lp(a) consensus statement

June 29, 2023

In a follow up to its 2022 consensus statement on lipoprotein(a) [Lp(a)],1 the European Atherosclerosis Society (EAS) has published the answers to 30 of the most frequently asked questions about how the recommendations affect everyday clinical practice and management of atherosclerotic cardiovascular disease (ASCVD).2  They include:

EAS updates Lp(a) Consensus Statement

August 30, 2022

The European Atherosclerosis Society (EAS) has published a new consensus statement on lipoprotein(a)1 which recognises the substantial body of evidence from genetic, epidemiological and Mendelian randomisation studies that has been built up since the first consensus paper was published.2 The risk for myocardial infarction (MI) increases at Lp(a) levels above the 75th percentile, whereas higher […]